

## Title Haemophilia A treatment

---

Reference Number: F2472-24

Date of Response: 23/04/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

*Q1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease.*

<i>Haemophilia A</i>	<i>Mild</i>	<i>Moderate</i>	<i>Severe</i>
43	24	*<5	15

*Q2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?*

<i>Advate</i>	*<5
<i>Adynovi</i>	0
<i>Elocta</i>	*<5
<i>Esperoct</i>	0
<i>Factor Eight Inhibitor Bypass Activity (FEIBA)</i>	0
<i>Hemlibra (standalone)</i>	0
<i>Hemlibra in combination with any Factor VIII</i>	0
<i>NovoEight</i>	0
<i>NovoSeven RT</i>	*<5
<i>Nuwiq</i>	0
<i>Obizur</i>	0
<i>Refacto AF</i>	*<5
<i>Any other products</i>	0

Q3. For patients treated with Advate in the last three months, please provide:

- the number of haemophilia A patients treated prophylactically.
- the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds)

The information requested in this question is not held by the Trust in a reportable format. The only data that is held is part of a patient's medical record held within the Electronic Patient Record (EPR). This data would not be appropriate to release under FOI as it is personal data and would not be lawful or transparent to patients to view their records for this purpose. As such it is exempt under Section 40(2) of the FOI Function as it is in breach of Principle 1 of the UK GDPR.

Q4. In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY?

<i>Advate</i>	*<5
<i>Adynovi</i>	0
<i>Elocta</i>	*<5
<i>Esperoct</i>	0
<i>Factor Eight Inhibitor Bypass Activity (FEIBA)</i>	0
<i>Hemlibra (standalone)</i>	0
<i>Hemlibra in combination with any Factor VIII</i>	0
<i>NovoEight</i>	0
<i>NovoSeven RT</i>	*<5
<i>Nuwiq</i>	0
<i>Obizur</i>	0
<i>Refacto AF</i>	*<5
<i>Any other products</i>	0

\*<5 Section 40 (2) when applicable:

Please note that in accordance with Section 40 (2) where activity is 5 or less than 5, the Trust is unable to provide the exact information. We consider the data exempt on the following grounds:

The Trust considers that disclosure of the information risks identifying individuals.

The reason for this is that the number of patients for which this applies is very low.

This and the fact that the data requested relates to the RDUH Health NHS Trust only

and therefore relates to patients treated in a specific location (rather than covering a larger geographical area), increases the risk of identification or self-identification. The Trust's view is that Section 40(2) is applicable because disclosure of information which could lead to a patient being identified would be a breach of the patient's rights under the Data Protection Act Data Protection Principles set out in Schedule 1 of the GDPR, namely Principle 1.